Food and Fermentation Industries >

2023 , Vol. 49 >Issue 6: 10 - 17

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.032391

Promoting effect of Bifidobacterium pseudocatenulatum W112 on immune checkpoint blockade therapy

  • LYU Mengxin ,
  • WU Jiangtao ,
  • ZHAO Jingqi ,
  • JIA Longgang ,
  • WANG Yanping ,
  • GENG Weitao
Expand
  • (College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin 300457, China)

Received date: 2022-05-20

  Revised date: 2022-06-10

  Online published: 2023-04-14

Fold

Abstract

In this study, we analyzed the promoting effect of Bifidobacterium pseudocatenulatum W112 on PD-1 antibody immunotherapy. The melanoma mouse model was established by subcutaneous injection of B16-F10 melanoma cells into the back of mice. Then the tumor bearing mice were treated with PD-1 antibody, intragastric administration of B. pseudocatenulatum W112 and their combination. Results showed that intragastric administration of B. pseudocatenulatum W112 increased the tumor inhibition rate in PD-1 antibody treatment, including the increasing of survival rate of mice, infiltration of CD8+T cells in tumor tissues, and the enrichment of interleukin-12 (IL-12) and interferon-γ (IFN-γ) in tumor tissues. The metagenome sequencing analysis of the microbiota in mice feces showed that intragastric administration of B. pseudocatenulatum W112 increased the diversity of mouse intestinal flora, promoted the enrichment of beneficial bacteria and reduced the enrichment of harmful bacteria. This study shows that B. pseudocatenulatum W112 has potential application in promoting immune checkpoint therapy.

Key words： Bifidobacterium pseudocatenulatum W112; intestinal flora; melanoma; immune checkpoint blockade

Cite this article

LYU Mengxin , WU Jiangtao , ZHAO Jingqi , JIA Longgang , WANG Yanping , GENG Weitao . Promoting effect of Bifidobacterium pseudocatenulatum W112 on immune checkpoint blockade therapy[J]. Food and Fermentation Industries, 2023 , 49(6) : 10 -17 . DOI: 10.13995/j.cnki.11-1802/ts.032391

References

[1] GUO J K, QIN S K, LIANG J, et al.Chinese guidelines on the diagnosis and treatment of melanoma(2015 Edition)[J].Annals of Translational Medicine, 2015, 3(21):322.
[2] SCHADENDORF D, VAN AKKOOI A C J, BERKING C, et al. Melanoma[J].The Lancet, 2018, 392(10151):971-984.
[3] SIEGEL R L, MILLER K D, DVM A J, et al.Cancer statistics, 2017[J].CA:A Cancer Journal for Clinicians, 2017, 67(1):7-30.
[4] CSCO黑色素瘤专家委员会.中国黑色素瘤诊治指南[M].北京:人民卫生出版社, 2013, 17:29-30.
Chinese Society of Clinical Oncology. Chinese Guidelines for Diagnosis and Treatment of Melanoma[M].Beijing: People's Medical Publishing House, 2013:17,29-30.
[5] MELLMAN I, COUKOS G, DRANOFF G.Cancer immunotherapy comes of age[J].Nature, 2011, 480(7 378):480-489.
[6] KROEMER G, ZITVOGEL L.The breakthrough of the microbiota[J].Nature Reviews Immunology, 2018, 18(2):87-88.
[7] CHEN W G, LIU F L, LING Z X, et al.Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer[J].PLoS One, 2012, 7(6):e39743.
[8] WANG T T, CAI G X, QIU Y P, et al.Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers[J].The ISME Journal, 2012, 6(2):320-329.
[9] WEI H, DONG L, WANG T T, et al.Structural shifts of gut microbiota as surrogate endpoints for monitoring host health changes induced by carcinogen exposure[J].FEMS Microbiology Ecology, 2010, 73(3):577-586.
[10] MARCHESI J R, DUTILH B E, HALL N, et al.Towards the human colorectal cancer microbiome[J].PLoS One, 2011, 6(5):e20447.
[11] VÉTIZOU M, PITT J M, DAILLÈRE R, et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J].Science, 2015, 350(6 264):1 079-1 084.
[12] PITT J M, VEÉTIZOU M, GOMPERTS BONECA I, et al.Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota[J].Oncoimmunology, 2016, 6(1):e1132137.
[13] SIVAN A, CORRALES L, HUBERT N, et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J].Science, 2015, 350(6 264):1 084-1 089.
[14] FRANKEL A E, COUGHLIN L A, KIM J, et al.Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint ttherapy efficacy in melanoma patients[J].Neoplasia, 2017, 19(10):848-855.
[15] CHAPUT N, LEPAGE P, COUTZAC C, et al.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J].Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017, 28(6):1 368-1 379.
[16] HERBST R S, SORIA J C, KOWANETZ M, et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J].Nature, 2014, 515(7 528):563-567.
[17] TUMEH P C, HARVIEW C L, YEARLEY J H, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature, 2014, 515(7 528):568-571.
[18] EROGLU Z, ZARETSKY J M, HU-LIESKOVAN S, et al.High response rate to PD-1 blockade in desmoplastic melanomas[J].Nature, 2018, 553(7 688):347-350.
[19] JIN Y P, DONG H, XIA L L, et al.The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC[J].Journal of Thoracic Oncology, 2019, 14(8):1 378-1 389.
[20] GOPALAKRISHNAN V, SPENCER C N, NEZI L, et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J].Science, 2018, 359(6 371):97-103.
[21] WANG W C, WANG Y, SHI L H, et al.Programmed death 1/programmed death ligand 1 signaling pathway in tumor immunotherapy:An update[J].Academic Journal of Second Military Medical University, 2017, 38(9):1 190-1 195.
[22] DESHPANDE G, RAO S, PATOLE S.Progress in the field of probiotics:Year 2011[J].Current Opinion in Gastroenterology, 2011, 27(1):13-18.
[23] SALGIA N J, BERGEROT P G, MAIA M C, et al.Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors[J].European Urology, 2020, 78(4):498-502.
[24] MATSON V, FESSLER J, BAO R Y, et al.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients[J].Science, 2018, 359(6 371):104-108.
[25] SHI L L, SHENG J Y, CHEN G Z, et al.Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance[J].Journal for ImmunoTherapy of Cancer, 2020, 8(2):e000973.
[26] RAFTER J, BENNETT M, CADERNI G, et al.Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients[J].The American Journal of Clinical Nutrition, 2007, 85(2):488-496.
[27] MCQUADE J L, DANIEL C R, HELMINK B A, et al.Modulating the microbiome to improve therapeutic response in cancer[J].The Lancet Oncology, 2019, 20(2):e77-e91.
[28] ROUTY B, LE CHATELIER E, DEROSA L, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J].Science, 2018, 359(6 371):91-97.
Options
Outlines

/

〈 〉

Powered by Beijing Magtech Co. Ltd,.